DNA methylation was first described almost a century ago; however, the rules governing its establishment and maintenance remain elusive. Here we present data demonstrating that active transcription regulates levels of genomic methylation. We identify a novel RNA arising from the CEBPA gene locus that is critical in regulating the local DNA methylation profile. This RNA binds to DNMT1 and prevents CEBPA gene locus methylation. Deep sequencing of transcripts associated with DNMT1 combined with genome-scale methylation and expression profiling extend the generality of this finding to numerous gene loci. Collectively, these results delineate the nature of DNMT1-RNA interactions and suggest strategies for gene-selective demethylation of therapeutic targets in human diseases.
DNA methylation is a key epigenetic signature implicated in transcriptional regulation, genomic imprinting, and silencing of repetitive DNA elements 1,2 that occurs predominantly within CpG dinucleotides. CpG dinucleotides are underrepresented in the mammalian genome (,1%) and tend to cluster within CpG islands located in the vicinity of the transcription start sites (TSSs) of the majority (,70%) of human protein-coding genes 3 . Although the bulk of genome is methylated at 70-80% of its CpGs, CpG islands are mostly unmethylated in somatic cells 3, 4 . This modification is mediated by the members of the DNA methyltransferase (DNMT) family, conventionally classified as de novo (DNMT3a and DNMT3b) and maintenance (DNMT1). In terms of epigenetic inheritance, DNMT1 has the unique ability of identifying the hemimethylated portion of newly replicated DNA. This feature may explain how DNMT1-mediated methylation could be an epigenetic mechanism maintaining the status quo. However, it certainly does not explain how DNA methylation is altered, particularly in disease states.
To examine how transcription may regulate the levels of genomic methylation, we investigated methylation dynamics of the well-studied methylation-sensitive gene CEBPA [5] [6] [7] , including the potential involvement of non-coding RNAs (ncRNAs) originating within the CEBPA locus. Recent discoveries of functional ncRNAs have provided new regulatory clues to the control of epigenetic marks. In particular, long ncRNAs have been shown to regulate gene expression by interacting with chromatin modifiers, modulating transcription factor activity and competing for microRNA binding [8] [9] [10] [11] [12] [13] [14] [15] [16] . One unexplored aspect of the regulation of gene locus DNA methylation was the possible involvement of transcripts encoded within the region.
We identified a functional RNA arising from the CEBPA locus, ecCEBPA, that regulates CEBPA methylation. This RNA interacts with DNMT1, resulting in prevention of CEBPA gene methylation and robust CEBPA messenger RNA production. We show that such functional DNMT1-RNA association occurs at numerous gene loci. We thus propose a novel regulatory mechanism of gene methylation governed by RNAs.
Characterization of ecCEBPA
Non-coding transcripts arising from the promoter and the downstream regions of coding genes can affect the expression of the corresponding genes [17] [18] [19] . We searched and identified transcripts upstream and downstream of the intronless CEBPA gene. Strand-specific reverse transcriptase PCR (RT-PCR; data not shown) and northern blot analysis of RNAs from four leukaemic cell lines, probing the region immediately after the CEBPA polyadenylation site, revealed the presence of a major band of ,4.5 kilobases (kb) in HL-60 and U937 (in which CEPBA is expressed), but not in K562 or Jurkat (in which CEBPA is expressed at low or undetectable levels), cell lines ( Fig. 1a, b ). The identified transcript is distinct from the ,2.6 kb signal, detected with a CEBPA codingregion probe, and correlates with CEBPA mRNA expression. Unlike polyadenylated CEBPA mRNA ( Fig. 1c ), this non-polyadenylated transcript is enriched in the nuclear fraction ( Supplementary Fig. 1a, b ), suggesting functional roles independent of protein-coding potential.
We termed this nuclear non-polyadenylated CEBPA ncRNA extracoding CEBPA (ecCEBPA), as it encompasses the entire mRNA sequence in the same-sense orientation (shown by primer extension and 59 and 39 rapid amplification of complementary DNA ends (RACE); Supplementary Information and Supplementary Fig. 1c, d) . Quantitative (q)RT-PCR analysis confirmed concordant expression between extra-coding and coding transcripts, in both cellular and nuclear RNAs (Fig. 1d, e ). Similar correlation was observed in all tested human tissues (Supplementary Fig. 1e ). Notably, ecCEBPA synthesis precedes the expression of its overlapping mRNA in the S phase (Supplementary Information and Supplementary Fig. 1f , g) and is regulated by both RNA polymerase (RNAP) II and III (Supplementary Information and Supplementary  Fig. 1h -p), as described for other loci [20] [21] [22] .
ecCEBPA blocks methylation and maintains CEBPA mRNA To examine the functional role of ecCEBPA in the regulation of CEBPA transcription, we performed both loss-and gain-of-function experiments. Knockdown of ecCEBPA in a U937 cell line (up to a fourfold decrease) achieved by short hairpin RNAs (shRNAs) targeting ecCEBPA (but not CEBPA mRNA) led to a decrease of CEBPA mRNA expression of similar magnitude ( Fig. 2a, b ), suggesting that ecCEBPA may regulate CEBPA expression. Silencing of the CEBPA gene can be associated with DNA methylation of the promoter 6, 7, 23 . To examine whether there was a connection between ecCEBPA and methylation of the CEBPA locus, we analysed methylation within the distal promoter (located at 20.8 to 20.6 kb from the CEBPA TSS; Fig. 2a ). Intriguingly, ecCEBPA knockdown led to a significant increase in DNA methylation compared to the non-targeting control ( Fig. 2c and Supplementary Fig. 2a ).
To investigate whether enforced expression of ecCEBPA was sufficient to inhibit DNA methylation, the downstream region of ecCEBPA (R1; Fig. 2a ) was overexpressed in K562 cells expressing ecCEBPA and CEBPA mRNA at low-to-undetectable levels ( Fig. 1b, d ). Overexpression of only part of ecCEBPA was dictated by the necessity to distinguish the methylation pattern of the endogenous CEBPA locus from that of the ectopically expressed construct.
Ectopic expression of ecCEBPA R1 resulted in greater-than-threefold increase in mRNA expression ( Fig. 2d ), whereas overexpression of an unrelated region (located 45 kb downstream) and regions immediately outside of the ecCEBPA boundaries did not affect mRNA levels (Supplementary Fig. 2b-d ). Moreover, a concomitant decrease of DNA methylation in three tested regions within the CEBPA gene, distal promoter, coding region and 39 untranslated region accompanied overexpression of ecCEBPA but not of the unrelated region ( Fig. 2e and Supplementary Fig. 2e , f). Interestingly, comparative analysis of DNA methylation changes imposed by ecCEBPA overexpression versus the hypomethylating agent 59-azacytidine (5-aza-CR), together with genomescale analysis (reduced representation bisulphite sequencing; RRBS 24 ) of DNA methylation changes imposed by ecCEBPA versus unrelated region overexpression, revealed that ecCEBPA-mediated demethylation was relatively selective to the CEBPA locus ( Supplementary Fig.  2g -l). Indeed, increased mRNA expression and changes in methylation status within the loci of the neighbouring CEBPG and distant TP73 (on chromosome 1p36) genes were achieved after 5-aza-CR treatment but not after ecCEBPA overexpression ( Supplementary Fig. 2g-k 
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were hypomethylated at levels similar to the CEBPA locus (Supplementary Fig. 2l ). Furthermore, ecCEBPA downregulation by the universal RNAP inhibitor actinomycin D and RNAP III-specific inhibitor ML-60218 ( Supplementary Fig. 2m ) led to a corresponding increase in methylation of the CEBPA locus, in synchronized and unsynchronized U937 cells ( Fig. 2f , g and Supplementary Fig. 2n ). Despite comparable decreases in ecCEBPA levels in both synchronized and unsynchronized cells (Fig. 2f ), DNA methylation increase was more prominent in synchronized cells ( Fig. 2g ), suggesting a cell-cycle-specific action of the ecCEBPA. A similar effect was observed in ML-60218-treated HL-60 cells ( Supplementary Figs 1i and 2o) .
Consistently, we observed an inverse correlation between the CEBPA gene locus methylation and the levels of ecCEBPA in HL-60, U937 and K562 cell lines ( Supplementary Fig. 2p ).
Collectively, these data highlight the regulatory role of ecCEBPA in CEBPA gene locus methylation, most prominently during the S phase.
DNMT1 binds to RNA with greater affinity than to DNA
The changes in CEBPA methylation mediated by ecCEBPA prompted us to try to determine the mechanism through which it is achieved. Among DNMTs, it is DNMT1 whose expression and enzymatic activity peaks during S phase 25 . Increased ecCEBPA expression occurs during the S phase ( Supplementary Fig. 1g ), whereas inhibition of ecCEBPA during S phase results in a substantial increase of CEBPA locus DNA methylation ( Fig. 2f , g and Supplementary Fig. 2n ). We therefore asked whether the presence of ecCEBPA during S phase led to RNA interference of DNMT1 activity.
To determine whether DNMT1 physically associates with ecCEBPA we performed RNA immunoprecipitation (RIP) with specific anti-DNMT1 antibody ( Supplementary Fig. 3a ).We observed ecCEBPA enrichment in DNMT1-RNA precipitates, demonstrating a physical interaction between ecCEBPA and DNMT1 ( Fig. 3a, b and Supplementary Fig. 3a ). Analysis of polyadenylated (poly(A) 1 ) and nonpolyadenylated (poly(A) 2 ) fractions in DNMT1-RNA precipitates revealed enrichment of CEBPA transcripts in the poly(A) 2 fraction ( Supplementary Fig. 3b , c), suggesting that the major component of CEBPA transcripts in DNMT1-RNA precipitates was ecCEBPA.
To investigate the molecular properties of RNA-DNMT1 interaction in vitro, we performed (RNA) electrophoresis mobility shift assays ((R)EMSAs). RNA oligonucleotides corresponding to the 59and 39 parts of ecCEBPA were selected by: (1) the ability (R2, R5 and R6) and inability (R4) to fold into stem-loop structures 26 ; and (2) the presence (R2, R5 and R6) or absence (R4) of CpG dinucleotides ( Fig. 3a) . RNA-DNMT1 complex formation was observed with all RNA oligonucleotides able to fold into stem-loop structures ( Fig. 3c-e ). Unlike DNA 27 , CpG to UpG substitutions, neutral with regard of secondary structures, did not affect binding (mutR2; Fig. 3c ). By contrast, mutations abrogating RNA folding ability affected RNA-DNMT1 binding (mut R5; Fig. 3e ). Analyses extended to a number of RNA oligonucleotides not related to ecCEBPA (single-stranded R1 and R3 and doublestranded R13; Supplementary Fig. 3d ) confirmed DNMT1 binding to stem-loop-structured RNAs (Supplementary Information and Supplementary Fig. 3e , f). Importantly, REMSAs performed in the presence of increasing concentrations of spermine, a molecule with four positive charges at high density, excluded a case of charge-charge interactions ( Supplementary Fig. 3g ), supporting a strong element of structural recognition between DNMT1 and RNA.
To determine the relative affinity of DNMT1 for ecCEBPA versus DNA, single-stranded RNA oligonucleotides capable of forming secondary structures (R5) and corresponding unmethylated doublestranded DNA (umDNA; D5/D6), hemimethylated double-stranded DNA (hmDNA; D5/D6) and fully methylated double-stranded DNA (mDNA; D5/D6) ( Fig. 3a) , at a constant molar concentration, were titrated with an increasing range of DNMT1 enzyme concentrations using EMSA. RNA formed complexes beginning at ,0.013 mM . Left and middle: RNA oligonucleotide R2 and its mutated form mut R2 (asterisks indicate cytosines substituted to uridines), both able to form stem-loop structures. d, RNA oligonucleotides able to form stem-loop structure bind DNMT1 (R6). e, R5 RNA oligonucleotide forming stem-loop structure (R5) has a greater DNMT1 affinity compared to mut R5, which is unable to fold into stem-loop (taken in equimolar amounts) at the same DNMT1 concentration. f, Left four panels, REMSA and EMSA performed with the fixed concentration of single-stranded RNA and double-stranded DNA oligonucleotides ( 
ARTICLE RESEARCH
DNMT1 and DNA at .0.026 mM DNMT1 (Fig. 3f) , with a mean dissociation constant (K d ) for RNA of 0.045 mM and between 0.082 and 0.14 mM for DNA, indicating that RNA has a stronger affinity for the enzyme than DNA (Fig. 3f ). Consistently, RNA unable to fold into stem-loop structures (R4; Fig. 3g ) did not display the same affinity for DNMT1 as 'folded' RNA (R5; Fig. 3f , g), demonstrating that RNA secondary structure represents an essential feature of RNA-DNMT1 complex formation.
Finally, to assess which DNMT1 domain is required for the RNA binding, DNMT1-glutathione S-transferase (GST)-purified domains (Fig. 3h ) were incubated with RNA oligonucleotides able or unable to fold into stem-loop structures (R5 and R4, respectively; Fig. 3e, g) . The catalytic domain, including the target recognition domain 28 shared by both fragments F4 and F5, selectively bound the 'folded' RNA oligonucleotide ( Fig. 3h ). Next, we deleted the DNMT1 region including the sequence overlapping F4 and F5. Unfortunately, even minimal removal of the target recognition domain led to disruption of DNMT1 enzymatic activity (data not shown), making further refinement of the binding domain unfeasible.
Collectively, these data indicate that RNA can associate with DNMT1. This interaction is not contingent upon the presence of CpG dinucleotides, is not a trivial ion pairing, and is dependent upon certain RNA secondary-structure features. Importantly, DNMT1, through its catalytic domain, binds with higher affinity to folded RNA than to DNA.
Transcription interferes with DNMT1 activity
To examine whether newly synthesized transcripts could interfere with the ability of DNMT1 to methylate hmDNA, we performed a combined in vitro transcription-DNA methylation assay. A hmDNA segment (bottom-strand methylated) was engineered downstream of the T7 RNAP promoter ( Supplementary Fig. 4a -h) and DNMT1 methylase activity was monitored in the presence and absence of transcription ( Fig. 4a-d ). In the absence of polymerase there was, as expected, increased DNA methylation of the upper strand ( Fig. 4d-f and Supplementary Fig. 4i-j) . By contrast, no changes in DNA methylation were observed in the presence of both polymerases and DNMT1 ( Fig. 4c-f and Supplementary Fig. 4i -j). Standard in vitro DNA methylation assays confirmed the enzymatic impairment of DNMT1 mediated by ribo-oligonucleotides ( Fig. 4g ). Similarly, T7 RNA polymerase 29 -induced transcription in living cells led to a pronounced decrease in DNA methylation (Supplementary Information and Supplementary Fig. 4k-p) .
Thus, RNA can complex with and affect DNMT enzymatic activity in vitro [30] [31] [32] and in living cells. These findings suggest that RNAs arising from methylation-sensitive genes and their promoters can regulate expression of the corresponding genes by interfering with DNA methylation.
RNA inhibition of DNA methylation is a global effect
Our observations suggested an inverse correlation between RNA-DNMT1 complexes and methylation of the CEBPA locus. Therefore, we sought to explore the extent of DNMT1-RNA association in other genomic loci with respect to DNA methylation and gene expression profiles. Complementary DNA libraries made of RNAs coimmunoprecipitated with anti-DNMT1 antibody (DNMT1 library) and IgG (control library) were tested for ecCEBPA enrichment ('quality control'; Supplementary Fig. 5a ) and subsequently analysed by massively parallel sequencing 11 . Using 76-base paired-end sequencing, we produced a total of 30.25 and 26.95 million pair reads for DNMT1 and control libraries, respectively (detailed analysis described in Methods). All significant DNMT1 peaks (a total of 16,186; P , 0.0001; false discovery rate of 7.5%) were annotated with CEAS 33 build on RefSeq hg19 (Supplementary Fig. 5b ). All DNMT1 peaks were also annotated using the known RNAs databases provided by HOMER 34 (Supplementary Fig. 5c ). We focused on genomic regions encompassing the 3 kb upstream of the TSS and downstream to the transcription ending site of the annotated genes, referred to as 'gene loci'. We identified 6,042 gene loci containing one or more peaks from the DNMT1 library (Methods).
To confirm that DNMT1 RIP-seq peaks were associated with actual transcribed elements, RNA-seq was conducted on poly(A) 2 HL-60 RNA. In total, 375 million 76-bp paired-end reads were aligned to hg19 using TopHat2 35 and assembled using Cufflinks 36 , and 14,077 (87.02%) of the specific DNMT1 peaks overlapped with a transcribed element from the RNA-seq assembly of the poly(A) 2 HL-60 RNA fraction. Thus, the vast majority of DNMT1-interacting RNAs (DiRs) were not polyadenylated.
In addition, we performed a similar analysis with total HL-60 RNA (300 million 76-bp paired-end reads). In total, 14,497 specific DNMT1 peaks (89.61%) were found to overlap with transcripts from the total HL-60 RNA-seq assembly. A merged assembly of the two RNA libraries validated a total of 15,238 (94.20%) DNMT1 RIP-seq peaks (Fig. 5a ). These findings confirmed the existence of DiRs on a genome-wide level. Next, we assessed the linkage between genomic loci giving rise to DiRs, levels of genomic methylation by RRBS 24 and expression of the corresponding nearby genes by microarray analysis, performed on HL-60 cells. Within all 15,806 RRBS-covered loci, 10,973 loci were not covered by DNMT1-specific peaks (DNMT1-unbound group) and 4,833 loci were covered by DNMT1-specific peaks (DNMT1-bound group). These 4,833 loci represent the majority (79.99%) of all 6,042 gene loci identified by DNMT1 RIP-seq ( Supplementary Fig. 5d ).
Within DNMT1-bound and -unbound groups, genes were stratified according to expression and methylation levels (the latter computed as the mean of all CpG b-scores from 22 kb from the TSS to the end of the first intron). A negative correlation between DNMT1-RNA Supplementary Fig. 4 ) with and without combinations of RNA polymerase, DNMT1, or both. NTPs, nucleotide triphosphates. e, DNMT1 exerts enzymatic activity only in the absence of transcription. Combined bisulphite restriction analysis assay (COBRA) analysis of methylation patterns acquired in reactions shown in b-d. f, DNA methylation changes are shown as the ratios of methylated to unmethylated CpGs in all clones analysed per construct (n 5 5). The same effect was observed with two different RNA polymerases: T7 and sigmasaturated (s70)-holoenzyme (Escherichia coli RNAP). DNA methylation changes were analysed by Fisher's exact test (***P , 0.001). g, In vitro DNMT1 assay demonstrating DNMT1 enzymatic impairment by RNA oligonucleotides. The assay was performed using ecCEBPA-related and -unrelated RNA oligonucleotides. Sequences and position of the ribooligonucleotides are shown in Fig. 3a and Supplementary Fig. 3 . Error bars indicate mean 6 s.d. (n 5 2).
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association with gene locus methylation status was observed (Supplementary Fig. 5e ).
Next, we clustered genes within both groups according to levels of expression and methylation. We defined genes as 'expressed' or 'low or not expressed' if the log 2 score was above or below 4, respectively; and 'hypomethylated' or 'methylated' if the mean of all CpG scores was below or above 50%, respectively (Methods). This approach allowed us to identify four clusters within DNMT1-unbound, DNMT1-bound, and all RRBS-covered groups (Fig. 5b) . Hypomethylated and expressed genes appeared to be predominant in the DNMT1-bound group (cluster C), accounting for 56.64%, whereas hypermethylated and low or unexpressed genes represented the 51.45% in the DNMT1-unbound group (cluster B). Moreover, the numbers of genes in clusters B (5,646 genes) and C (2,737 genes) were significantly higher than numbers of genes in clusters A, F, E (2,528, 1653, 1,146) and G, H, D (584, 930, 582), respectively (P , 0.0001). Examples of genes from clusters B and C are presented in Fig. 5c and Supplementary Fig. 5f-h) . Furthermore, genes from cluster C belonged to a multiplicity of biological processes, indicating the diversity of DiRs ( Supplementary Fig. 6a ). Interestingly, ,60% of these Biological Process Gene Ontology (BP-GO) terms (P # 0.01) were shared with pyknon (non-random pattern of repeated elements)-related BP-GO 37 . This overlap is 71-fold higher than expected. Moreover, among all DNMT1 RIP-seq peaks, 46% carry at least one pyknon ( Supplementary Fig. 6b ) suggesting a potential relation between DiRs and pyknons.
Grouping of genes in clusters A, F, E, G, H and D could result from technical limitations of RRBS, contingent upon the genomic location of the restriction sites and the DNA library size selection 38 , or these genes may be governed by yet another mechanism of transcriptional control.
In conclusion, we have generated the first comprehensive map cross-referencing DiRs to DNA methylation and gene expression. These data demonstrate that RNA-DNMT1 association is widespread and might modulate genomic DNA methylation (Fig. 5d ).
Discussion
This study explores the role of a new class of RNAs: DNMT1-interacting RNAs. Using the CEBPA gene as a model, we show that mRNA transcription is accompanied by the production of an additional RNA species, ecCEBPA. In every instance studied, DNA methylation levels are inversely correlated with ecCEBPA levels, and the extent of DNA methylation is determined by the absence or presence of ecCEBPA (Fig. 2) .
We demonstrate that ecCEBPA associates with DNMT1 and establish a functional link between ecCEBPA and CEBPA expression as through RNA-DNMT1 association.
We show that RNAs capable of adopting stem-loop structures exhibit the potential to associate with DNMT1, suggesting that the basis of this preferential interaction is recognition of RNA secondary structure ( Fig. 3) .
Importantly, we demonstrate that this type of RNA-DNMT1 association is not restricted to the CEBPA gene locus. We have globally identified RNA species associated with DNMT1 and their relationship to DNA methylation and gene expression. These alignments defined a large set of expressed unmethylated genes and a complementary set of silent methylated genes that could possibly be induced following expression of the DiR.
Our findings suggest a model of site-specific DNMT1 sequestration in which RNAs act as a shield, halting DNMT1 and thus modulating DNA genomic methylation at their site of transcription ( Fig. 5d) . Indeed, the loss of CEBPA locus methylation following overexpression of ecCEBPA does not support a model of trivial titration ('squelching' 39 ) of DNMT1 but suggests a cis-regulatory role of the DiR. We propose a model wherein RNAs contain a locus-selective triplex/quadruplex 40forming part, the 'anchor', mooring the DNMT1-RNA complex to the locus, and a DNMT1-interacting part, the 'bait', a stem-loop-likeforming sequence serving to lure the DNMT1 into association. DNMT1 sequestration by RNA does resemble a competing mechanism described for other regulatory RNAs, for example, competing endogenous RNAs 15, 16, 41 . However, unlike competing endogenous RNAs, the ecCEBPA model also introduces the requirements for both functional and physical co-compartmentalization of the RNA, its parental locus, and DNMT1. Given the ability of DiRs to bind DNMT1, it is tempting to suggest that DiRs represent a novel class of RNA regulons 42 .
Taken together, these data support the hypothesis that RNA participates in the establishment of genomic methylation patterns by interacting with DNMT1 and pave the way for the site-specific adjustments of aberrant DNA methylation.
METHODS SUMMARY
RIP-seq. Double-stranded cDNA from total RNA immunoprecipitated with DNMT1 antibody (Abcam) or IgG (Sigma Aldrich) was synthesized using the Just cDNA Double-Stranded cDNA Synthesis Kit (Agilent Technology) according to the manufacturer's instructions. cDNA libraries were paired-end sequenced on an Illumina GA IIx. MassARRAY and RRBS. MassARRAY and RRBS were performed as described 43, 44 . For RRBS, sequenced reads were mapped to the reference genome hg19 using RRBSmap 45 allowing two mismatches and gene loci were scored by Genome Bisulfite Sequencing Analyzer (GBSA) 46 . Differentially methylated domains were computed using the R/MethylKit package 47 
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Cell culture. All cell lines were obtained from ATCC and grown according to the manufacturer's instructions in the absence of antibiotics. The DNMT1 hypomorphic HCT116 cell line and its wild-type counterpart HCT116 were grown in McCoy's 5A modified medium supplemented with 10% FCS. RNA isolation and northern blot analysis. Total RNA isolation, electrophoresis, transfer and hybridization were carried out as described 49 . Cytoplasmic RNA was isolated with the Paris kit (Ambion) according to the manufacturer's recommendations. For the preparation of nuclear RNAs we used a method derived from protocols of nuclei isolation 50 , with minor modifications. In brief, equal amounts of viable cells (,50 million) were washed with ice-cold PBS supplemented with 5 mM vanadyl complex, 1 mM phenylmethylsulphonyl fluoride (PMSF) and resuspended in the ice-cold lysis buffer: 1 3 buffer A (10 mM HEPES-NaOH, pH 7.6, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 mM Na butyrate), 1.25 M sucrose, 10% glycerol, 5 mg ml 21 BSA, 0.5% NP-40, freshly supplemented with protease inhibitors (2 mM leupeptin, add as 3400; 2 mM pepstatin, add as 3400; 100 mM benzamidine, add as 3400; a protease inhibitor cocktail (Roche Applied Science), 1 tablet per 375 ml H 2 O, add as 3100; 100 mM PMSF, add as 3100), 2 mM vanadyl complex (New England Biolabs) and 20 units per ml RNase inhibitor (RNAguard; Amersham Biosciences). Samples were incubated at 0 uC for ,10 min and passed through 40 up-and-down strokes in a Dounce homogenizer (10 with pestle A and 30 with pestle B). The pelleted nuclei were resuspended in 0.5 ml lysis buffer and diluted with 2.25 ml dilution buffer (2.13 ml 'cushion' buffer plus 0.12 ml 0.1 g ml 21 BSA), freshly supplemented with protease inhibitors and overlaid onto 2 ml 'cushions' (20 ml cushion buffer consists of 15 ml double-deionized (dd)H 2 O, 15 ml 203 buffer A, 30 ml glycerol, 240 ml 2.5 M sucrose; freshly supplemented with protease inhibitors) into one SW 55 Ti tube and centrifuged at 100,000g for 60 min at 4 uC. The pelleted nuclei were re-suspended in 1 ml storage buffer (1.75 ml ddH 2 O, 2 ml glycerol, 0.2 ml 203 buffer A), freshly supplemented with protease inhibitors. Nuclear RNAs were extracted as described 50 . All total, cytoplasmic and nuclear RNA samples used in this study were treated with DNase I (10 U of DNase I per 3 mg of total RNA; 37 uC for 1 h; in the presence of RNase inhibitor). After DNase I treatment, RNA samples were extracted with acidic phenol (pH 4.3) to eliminate any remaining traces of DNA. Polyadenylated and non-polyadenylated RNA fractions were selected with the MicroPoly(A) Purist purification kit (Ambion). cDNA syntheses were performed with Random Primers (Invitrogen) with Transcriptor Reverse Transcriptase (Roche Applied Science) according to the manufacturer's recommendation. cDNA was purified with a High Pure PCR Product Purification Kit (Roche Applied Science). qRT-PCR. SYBR green reactions were performed using iQ Sybr Green supermix (Bio-Rad); PCR conditions: 95 uC (10 min) followed by 40 cycles of 95 uC (15 s) and 60 uC (1 min) and 72 uC (1 min). TaqMan analysis was performed using Hotstart Probe One-step qRT-PCR master mix (USB); PCR conditions: 50 uC (10 min), 95 uC (2 min), followed by 40 cycles of 95 uC (15 s) and 60 uC (60 s). Primers and probes are presented in Supplementary Methods. qRT-PCR primer set for the CEBPA mRNA is located in the coding region (black double-headed arrow in Fig. 1a ) and after the poly(A) signal for ecCEBPA (white double-headed arrow Fig. 1a) . Primer extension and 59/39 RACE. cDNA from the HL-60 cell line was synthesized as described above and run in alkaline conditions 51 . Southern blot transfer and hybridization with oligonucleotide AL16 were performed as reported previously 51 . Oligonucleotide sequences are shown in Supplementary Methods. 59/39 RACE was performed on two myeloid cell lines-HL-60 and U937-using the Exact START Eukaryotic mRNA 59-& 39-RACE Kit (Epicentre) according to the manufacturer's instructions. See Supplementary Methods for primer sequences. Double thymidine block (early S phase block). HL-60 cells were grown to 70-80% confluence, washed twice with 1 3 PBS and cultured in DMEM (10% FCS) plus 2.5 mM thymidine for 18 h (first block). Thymidine was washed out with 1 3 PBS and cells were grown in DMEM (10% FCS). After 8 h cells were cultured in the presence of thymidine for 18 h (second block) and then released as described. Synchrony was monitored by flow cytometry analysis (propidium iodide staining) using a LSRII flow cytometer (BD Biosciences) at the Harvard Stem Cell Institute/Beth Israel Deaconess Medical Center flow cytometry facility. DRB, ML-60218, a-amanitin and actinomycin D treatment. After release from double thymidine block, HL-60 cells were treated with 100 mM 5,6-dichlorobenzimidazole 1-b-D-ribofuranoside 52 (DRB; Sigma-Aldrich) for 1, 2 and 3 h. HL-60 cells were treated with 12.5, 25, 50 or 100 mM ML-60218 (refs 53, 54; Calbiochem) for 24 h. HL-60 cells were treated with 5, 23, 50, 75, 100 or 150 mg ml 21 a-amanitin (Sigma-Aldrich) for 14 h. Synchronized and unsynchronized U937 cells were treated with ML-60218 at 100 mM and actinomycin D (Sigma-Aldrich) at 150 mM for 7 h. Total RNA was collected as described above and expression levels of CEBPA, ecCEBPA and 5S were measured by TaqMan qRT-PCR.
Nuclear chromatin immunoprecipitation and RIP. Chromatin immunoprecipitation (ChIP) was performed as described previously 19 . Fold enrichment was calculated using the formula 2 (2DDCt(ChIP/non-immune serum)) . Antibodies used for ChIP are listed in Supplementary Table 1. RIP was performed as described in ref. 14. Day 1: crosslinked nuclei were collected as follows: 60 3 10 6 HL-60 cells were crosslinked with 1% formaldehyde (HCHO; formaldehyde solution, freshly made: 50 mM HEPES-KOH, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 11% formaldehyde) for 10 min at room temperature (21 uC) . Crosslinking was stopped by adding one-tenth the volume of 2.66 M glycine, kept for 5 min at room temperature and 10 min on ice. Cell pellets were washed twice with ice-cold PBS (freshly supplemented with 1 mM PMSF). Cell pellets were re-suspended in cell lysis buffer (volume 4 ml): 1 3 buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 0.5% NP-40, freshly supplemented with protease inhibitors (protease inhibitors cocktail: Roche Applied Science, 1 tablet per 375 ml H 2 O; add as 3100), 1 mM PMSF and 2 mM vanadyl complex (NEB). Cells were incubated at 0 uC for 10-15 min and homogenized by Dounce (10 strokes with pestle A and 40 strokes with pestle B). Nuclei were recovered by centrifugation at 2,000 r.p.m. for 10 min at 4 uC. Nuclei were re-suspended in 3 ml 1 3 re-suspension buffer (50 mM HEPES-NaOH, pH 7.4, 10 mM MgCl 2 ) supplemented with 1 mM PMSF and 2 mM vanadyl complex. DNase treatment (250 U ml 21 ) was performed for 30 min at 37 uC, and EDTA (final concentration 20 mM) was added to stop the reaction. Re-suspended nuclei were sonicated once for 20 s (1 pulse every 3 s) at 30% amplitude (Branson Digital Sonifer). Immunoprecipitation for RIP was performed as follows: before preclearing, the sample was adjusted to 1% Triton X-100, 0.1% sodium deoxycholate, 0.01% SDS, 140 mM NaCl, protease inhibitors, 2 mM vanadyl complex and 1 mM PMSF to facilitate solubilization. Preclearing step: ,50 ml magnetic beads (Protein A or G Magnetic Beads, NEB) were added to the sample and incubation was carried out for 1 h on a rocking platform at 4 uC. Beads were removed in a magnetic field. The sample was divided into three aliquots: (1) ecCEBPA, CEBPA and 18S expression levels were measured by qRT-PCR using the TaqMan primer sets indicated in Supplementary Methods. Downregulation of ecCEBPA. Three different shRNAs targeting human ecCEBPA and scrambled control were designed according to Dharmacon software and cloned into the lentiviral vector pLKO.1 (Sigma-Aldrich), which has a puromycin selection marker. shRNA sequences are shown in Supplementary Methods. Lentiviral particles were produced as described previously 55 . HEK293T cells were cotransfected with either empty vector or the pLKO-shRNA vector and Gag-Pol and Env constructs using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's recommendation. Virus-containing supernatants were collected 48 and 72 h after transfection and concentrated using a Centricon Plus-70 molecular weight cut-off column (Millipore). Lentiviral transduction was performed in the presence of hexadimethrine bromide (final concentration 8 mg ml 21 ) in the human myeloid cell line U937. Puromycin (2 mg ml 21 ) was added to the cultures 2 days after infection. Resistant clones were selected and screened for downregulation of ecCEBPA by qRT-PCR.
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Upregulation of ecCEBPA. The 39 ecCEBPA region (R1), the upstream and downstream ecCEBPA regions, and the unrelated genomic region (UR, see Supplementary Methods) were cloned into the pBabe retrovirus vector harbouring a puromycin selection marker (Addgene; plasmid 1764). Oligonucleotide sequences used to amplify both regions are shown in Supplementary Methods. K562 cells were transfected with the Amaxa Cell Line Nucleofector Kit V, Program T-003. Puromycin (2 mg ml 21 ) was added to the cultures 2 days after transfection. Resistant clones were selected and screened for upregulation of ecCEBPA and the UR by northern blot analysis. Bisulphite treatment, COBRA and bisulphite sequencing. The methylation profile of the CEBPA gene locus was performed by bisulphite sequencing as described previously 56 . In brief, 1 mg of genomic DNA was bisulphite-converted by using the EZ DNA Methylation kit (Zymo Research). Primers and PCR conditions for bisulphite sequencing and COBRA are summarized in Supplementary Methods. For COBRA, PCR products were gel-purified and incubated with BstUI at 60 uC for 3 h. The digested DNA was then separated on a 3.5% agarose gel and stained with ethidium bromide. For bisulphite sequencing, PCR products were gel-purified (Qiagen) and cloned into the pGEM-T Easy Vector System (Promega). Sequencing results were analysed using BiQ analyser software 57 . Samples with conversion rate , 90% and sequences identity , 70% as well as clonal variants were excluded from our analysis 55 . The minimum number of clones for each sequenced condition was $6. Primer sequences are shown in Supplementary Methods. 5-aza-CR treatment. K562 cells were treated with 5-aza-CR 58 (Sigma-Aldrich) according to the manufacturer's instructions. Medium was refreshed every 48 h. RNA (for RT-PCR) and genomic DNA (for bisulphite sequencing) were isolated after 7 days of treatment.
MassARRAY. Quantitative DNA methylation analysis using the MassARRAY technique was performed by Sequenom as described previously 43 . In brief, 1 mg of genomic DNA was converted with sodium bisulphite using the EZ DNA methylation kit (Zymo Research), PCR amplified, in vitro transcribed and then cleaved by RNase A. The samples were then quantitatively tested for their DNA methylation status using matrix-assisted laser desorption ionization-time of flight mass spectrometry. The samples were desalted and spotted on a 384-pad SpectroCHIP (Sequenom) using a MassARRAY nanodispenser (Samsung), followed by spectral acquisition on a MassARRAY Analyzer Compact MALDI-TOF MS (Sequenom). The resulting methylation calls were obtained using the EpiTyper software v1.0 (Sequenom) to generate quantitative results for each CpG site or an aggregate of multiple CpG sites. The methylation levels of aggregated multiple CpGs were calculated as the mean of each CpGs methylation value and presented as a percentage. Primer sequences are provided in Supplementary Data 1. Transfection of human DNMT1-haemagglutinin tag construct and western blot analysis. The human DNMT1-haemagglutinin-tagged cloned into the expression vector pCDNA3.1 was a kind gift from S. Baylin. HEK293T cells were transfected using Lipofectamine 2000, and 2 days later collected for western blot analysis. Single-cell suspensions were lysed with modified radioimmunoprecipitation assay buffer, and whole-cell lysates separated on 6% SDS-PAGE gels. Immunoblots were stained with the following primary antibodies: DNMT1 (1:5,000, Abcam) and HSP90 (1:2,000, BD Biosciences). All secondary antibodies were horseradish peroxidase (HRP)-conjugated (Santa Cruz) and diluted 1:5,000 for rabbit-HRP, and 1:3,000 for mouse-HRP. Western blot analysis for the HCT116 hypomorphic and wild-type cell lines were similarly performed. T7 polymerase-induced transcription. The T7 expression system is based on technology developed at Brookhaven National Laboratory under contract with the US Department of Energy and is the subject of patents and pending applications. Full information may be obtained from the Office of Intellectual Property and Sponsored Research, Brookhaven National Laboratory. Maps of T7 polymerase constructs are presented in ref. 59 . In brief, the murine RAW 264.7 cell line was stably transfected with a construct carrying the human genomic segment under T7 promoter control (derived from pBlueScript plasmid; Agilent). After selection in G418, individual clones were transfected with T7 polymerase-expressing mammalian constructs and were tested by COBRA for genomic methylation. EMSAs and K d determination. DNA and RNA oligonucleotides (15 pmol) were end-labelled with [c-32 P]ATP (Perkin Elmer) and T4 polynucleotide kinase (New England Biolabs). Reactions were incubated at 37 uC for 1 h and then passed through G-25 spin columns (GE Healthcare) according to the manufacturer's instructions to remove unincorporated radioactivity. Labelled samples were gelpurified on 10% polyacrylamide gels. Binding reactions were carried out in 10-ml volumes in the following buffer: 5 mM Tris, pH 7.4, 5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 3% (v/v) glycerol, 100 mM NaCl. Various amounts (0.021-0.156 mM) of purified DNMT1 protein (BPS Bioscience) were incubated with 1.1 nM of 32 P-labelled double-stranded DNA and single/double-stranded RNAs. In the competitive assay, a fixed amount of protein and increasing amounts of competitors (double-stranded DNA or poly(dI-dC)) were used. All reactions were assembled on ice and incubated at room temperature. Samples were separated on 6% native polyacrylamide gels (0.5 3 Tris/Borate/EDTA (TBE); 4 uC; ,3 h at 140 V). Gels were dried and exposed to X-ray film and/or PhosphoroImager screens. Quantification was done with ImageQuant software. For affinity assays, the per cent shifted species was determined as follows: the migration of the labelled DNA in this reaction was defined as zero per cent shifted and the ratio of the PhosphoroImager counts in the area of the lane above this band to the total counts in the lane was defined as background and subtracted from all other lanes. This band represented total input. Subsequent lanes containing DNMT1-nucleic acid complexes were treated identically, and the percentage complex formation was calculated as follows: [% bound complex 5 (1 2 ((unbound 2 background)/(input 2 background))]. All experiments contained a control reaction lacking DNMT1. The percentage complex formation was plotted as a function of DNMT1 concentration using nonlinear regression analysis performed with Prism 4.0a software. RNA and DNA oligonucleotides used in EMSA are shown in Fig. 3a and Supplementary  Fig. 3d and listed in Supplementary Methods. ecCEBPA binding to GST-DNMT1 fragments. GST and GST-DNMT1 fragments were expressed and purified by glutathione sepharose affinity beads (GE Healthcare Life Sciences) as described previously 60 . Protein concentrations for the recombinant GST and GST-DNMT1 fragments were determined by gel electrophoresis and subsequent Coomassie staining and densitometry. 32 P end-labelling of ecCEBPA oligonucleotides was carried out at 37 uC for 30 min in a total volume of 50 ml. The reaction contained 50 pmol ecCEBPA, adenosine 59-triphosphate, [c-32 P] (specific activity 3,000 Ci mmol 21 , Perkin Elmer) and 20 U of T4 kinase (New England Biolabs) mixed in assay buffer (70 mM Tris-HCl, 10 mM MgCl 2, 5 mM DTT, pH 7.6). The labelled ecCEBPA-32 P was purified with illustraMicroSpin G-25 Columns (GE Healthcare Life Sciences) according to manufacturer's specifications. Equal amounts of the GST and GST-DNMT1 fragments were mixed with 5 ml ecCEBPA-32 P, in duplicate, and incubated at 37 uC for 10 min in a total volume of 25 ml of reaction buffer (50 mM Tris-HCl, 1 mM DTT, 1 mM EDTA, 5% glycerol, pH 7.8). The sepharose beads were then washed four times in phosphatebuffered solution and placed in 3 ml of scintillation fluid and bound 32 P was measured for 1 min. All measurements were normalized to 32 P readings for the corresponding input 32 P-ecCEBPA. In vitro transcription-methylation assay. In vitro transcription-methylation assays were performed on hmDNA (described in Supplementary Information, legend to Supplementary Fig. 4) in the presence or absence of 5 U of human DNMT1 enzyme (New England Biolabs) and 5 U of T7 RNA polymerase (Promega) or 5 U of E. coli RNA polymerase sigma-saturated holoenzyme (Epicentre). Reactions were performed in DNMT1 buffer according to the manufacturer's recommendations supplemented with rNTPs (ribonucleotide triphosphates) and 1.25 mM MgCl 2 , including the 'DNMT1 only' reaction. This predetermined concentration of Mg 21 cations is high enough to sustain activity of RNA polymerases and low enough not to inhibit DNMT1 activity. DNMT1 in vitro methylation assay. DNMT1 enzymatic assays were carried out in duplicate at 37 uC for 30 min in a total volume of 25 ml. The reaction contained S-adenosyl-L-[methyl-3 H]methionine (AdoMet) (specific activity 18 Ci mmol 21 , Perkin Elmer), 200 ng of substrate DNA, recombinant DNMT1 enzyme (2.5 pmol) and ecCEBPA (2.5 pmol) mixed in assay buffer (50 mM Tris-HCl, 1 mM DTT, 1 mM EDTA, 5% glycerol, pH 7.8). Methyltransferase reactions were snap-frozen in an ethanol-dry ice bath. The entire reaction volume (25 ml) was spotted on 2.5-cm DE81 membranes (GE Healthcare). These membranes were processed by washes in 3 3 1 ml of 0.2 M ammonium bicarbonate, 3 3 1 ml water and 3 3 1 ml ethanol. Processed membranes were air-dried, placed in 3 ml of scintillation fluid and tritium incorporation was measured for 1 min. Background subtraction (no DNA substrate) was performed for all experimental sample counts. RIP-seq. Total RNA immunoprecipitated with DNMT1 antibody (Abcam) or IgG (Sigma-Aldrich) was processed for sequencing as described in ref. 61 with some modifications. Double-stranded cDNA was synthesized using the Just cDNA Double-Stranded cDNA Synthesis Kit (Agilent Technology) according to the manufacturer's instructions. Illumina sequencing libraries were constructed from these cDNA using a ChIP-seq sample preparation kit (Illumina) with minor modifications. Illumina paired-end adaptor and PCR primers were used to replace the single-read adaptor and primers in the kit. Constructed libraries were subjected to a final size-selection step on 10% Novex TBE gels (Invitrogen). DNA fragments of 175-200 base pairs (bp) were excised from a SYBR-green-stained gel. DNA was recovered from the gel and quantified following Illumina's qPCR quantification protocol. Paired-end sequencing of these libraries was then performed on an Illumina GA IIx to achieve 2 3 76-bp reads. Paired-end reads were trimmed to 50 bp and aligned to the reference genome hg19 using BWA 62 with the following parameters: bwa aln -o 1 -l 25 -k 2; bwa sampe -o 200. To estimate a normalization factor (alpha) between the immunoprecipitations, the genome was divided into course bins (10 kb) and reads were counted for DNMT1 RIP and IgG control in RESEARCH ARTICLE
